8-K - RenovoRx, Inc. (0001574094) (Filer)

10-K - RenovoRx, Inc. (0001574094) (Filer)

NT 10-K - RenovoRx, Inc. (0001574094) (Filer)

8-K - RenovoRx, Inc. (0001574094) (Filer)

424B5 - RenovoRx, Inc. (0001574094) (Filer)

424B5 - RenovoRx, Inc. (0001574094) (Filer)

8-K - RenovoRx, Inc. (0001574094) (Filer)

10-Q - RenovoRx, Inc. (0001574094) (Filer)

8-K - RenovoRx, Inc. (0001574094) (Filer)

8-K - RenovoRx, Inc. (0001574094) (Filer)

4 - RenovoRx, Inc. (0001574094) (Issuer)

4 - RenovoRx, Inc. (0001574094) (Issuer)

4 - RenovoRx, Inc. (0001574094) (Issuer)

4 - RenovoRx, Inc. (0001574094) (Issuer)

4 - RenovoRx, Inc. (0001574094) (Issuer)

4 - RenovoRx, Inc. (0001574094) (Issuer)

4 - RenovoRx, Inc. (0001574094) (Issuer)

4 - RenovoRx, Inc. (0001574094) (Issuer)

4 - RenovoRx, Inc. (0001574094) (Issuer)

4 - RenovoRx, Inc. (0001574094) (Issuer)

4 - RenovoRx, Inc. (0001574094) (Issuer)

4 - RenovoRx, Inc. (0001574094) (Issuer)

4 - RenovoRx, Inc. (0001574094) (Issuer)

4 - RenovoRx, Inc. (0001574094) (Issuer)

4 - RenovoRx, Inc. (0001574094) (Issuer)

4 - RenovoRx, Inc. (0001574094) (Issuer)

4 - RenovoRx, Inc. (0001574094) (Issuer)

4 - RenovoRx, Inc. (0001574094) (Issuer)

4 - RenovoRx, Inc. (0001574094) (Issuer)

4 - RenovoRx, Inc. (0001574094) (Issuer)

SC 13G/A - RenovoRx, Inc. (0001574094) (Subject)

SC 13G - RenovoRx, Inc. (0001574094) (Subject)

SC 13G - RenovoRx, Inc. (0001574094) (Subject)

SC 13G - RenovoRx, Inc. (0001574094) (Subject)

Roth Capital initiated coverage of RenovoRx with a rating of Buy and set a new price target of $16.00

Maxim Group initiated coverage of RenovoRx with a rating of Buy and set a new price target of $15.00

LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that Ryan Witt has joined the Company in the new role as Senior Vice President, Head of Corporate Strategy and Partnerships. Mr. Witt's appointment highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities not only for its RenovoGem™ investigational combination product (currently in Phase III clinical development), but also opportunities with the Company's foundational FDA

With Material Participation From Insiders, Offering Proceeds to Help Drive Company Towards Second Interim Analysis of the Pivotal TIGeR-PaC Phase III Clinical Trial by Late 2024 RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that it has closed a private placement (the "private placement" or the "financing") resulting in gross proceeds of approximately $6.1 million, before deducting offering expenses. The closing of this private placement extends RenovoRx's cash runway as RenovoRx continues its ongoing pivotal TIGeR-PaC Phase III c

RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Michel Ducreux, M.D., Ph.D. to the Company's Scientific Advisory Board (SAB). Dr. Ducreux is the Head of the Gastrointestinal Oncology Unit and Gastrointestinal Oncology Tumor Board at Gustave Roussy, Professor of Oncology at Paris-Saclay University in France, and Vice-Chair of ESMO GI. Dr. Ducreux was trained in medicine, gastroenterology, and gastrointestinal tract oncology at the University of Paris Sud. Dr. Ducreux earned his master's degree in biological sciences and PhD in health sciences. He has held pre

RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Margaret A. Tempero, M.D., Director, UCSF Pancreas Center and Leader of the UCSF Pancreas Cancer Program, to the Company's Scientific Advisory Board (SAB). "Dr. Tempero has been an international leader in the field of pancreatic cancer for decades and we look forward to working with her alongside the other members of our SAB," said Dr. Robert Spiegel, NCI-trained oncologist, former Chief Medical Officer of Schering Plough and RenovoRx Board Director. Dr. Tempero is Professor of Medicine, Division of Hematolog

RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a biopharmaceutical company focused on targeted drug-delivery with an initial application in locally advanced pancreatic cancer (LAPC), announced today that Robert J. Spiegel, MD, has been appointed to the Company's Board of Directors, effective April 25, 2023. Dr. Spiegel brings more than 40 years of biopharmaceutical experience to RenovoRx's Board. He was involved in more than 30 successful New Drug Application (NDA) approvals by the FDA and the development and launch of multiple products with annual sales exceeding $1B. While at Schering-Plough, he served as Sr. Vice President of Worldwide Clinical Research and Chief Medical O

RenovoRx, Inc. (NASDAQ:RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMPTM) therapy platform, today announced that Angela Gill Nelms has joined the company as Chief Operating Officer ("COO"). "Angela is a growth-oriented operational leader with experience in clinical trial management, a proven track record for driving innovation, and building high-functioning teams," said Shaun Bagai, CEO of RenovoRx. "Today, we are laser-focused on advancing our Phase 3 TIGeR-PaC clinical trial, launching our Phase 2/3 clinical trial in extrahepatic cholangiocarcinoma, and exp

RenovoCath is proudly made in America at a facility in North Barrington, IL RenovoRx management and board members purchased over 140,000 shares of RenovoRx stock during recent open trading window, signaling their confidence in RenovoRx's future RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced that it is increasing production of its FDA-cleared RenovoCath catheter-based device in order to meet increased demand for the targeted delivery of diagnostic and/or therapeutic agents from oncologists and interventional radiol

CEO Shaun Bagai to discuss the momentum of RenovoRx's commercialization efforts for its RenovoCath® device, including an update on initial revenues generated, and continued progress on the ongoing Phase III TIGeR-PaC clinical trial RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer Shaun Bagai will present at the LD Micro Invitational XV: New York 2025 conference taking place at the Westin Grand Central Hotel, New York, NY on April 10, 2025. Mr. Bagai will discuss recent corporate mileston

Revenues from RenovoCath Expected to Grow Sequentially During 2025 with Expansion of New Customer Purchase Orders and Customer Reorders Completion of TIGeR-PaC Clinical Trial Enrollment and Review of Second Interim Analysis by Data Monitoring Committee on Target for 2025 Reports 2024 Financial Results Including $7.2 Million Cash Position as of December 31, 2024, with Additional $12.1 Million in Gross Proceeds Raised in February 2025 Company to Host Fireside Chat on Thursday, April 3rd at 12 p.m. ET RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared dru

Data supports the novel Trans-Arterial Micro-Perfusion (TAMPTM) therapy platform for targeted chemotherapy delivery for the potential to minimize a therapy's toxicities versus systemic intravenous therapies Data shows localized, intra-arterial delivery of gemcitabine with FDA-cleared RenovoCath® device (known as IAG) resulted in lower systemic levels of drug compared to intravenous delivery of gemcitabine RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, announced today that a new human pharmacokinetic (PK) data abstract was presen

Peer-reviewed paper will be honored as a Journal of Vascular and Interventional Radiology Award-Winning Paper Pre-clinical data show that TAMP increases intra-arterial pressure, improving drug delivery with 100-fold increase in local tissue concentration of the therapy TAMP offers the potential to increase efficacy, improve safety and widen therapeutic window of existing and new treatments RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, is proud to announce that a publication supporting the Company's proprietary Trans-Arterial M

Initial Revenues Expected this Quarter, and Customer Pipeline for RenovoCath Standalone Device Continues to Expand, Including High Volume National Cancer Institute-Designated Centers RenovoCath Gaining Validation in an Initial U.S. Market Estimated at $400 Million Annually RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced continuing momentum with the Company's RenovoCath commercial strategy, with new purchase orders received from several esteemed, high volume National Cancer Institute-designated centers. Additionally,

Pre-Clinical Data Recently Presented at the SIO 2025 Annual Conference Show that Intra-Arterial Administration of a Drug with the RenovoCath® Delivery System via TAMP May Improve Delivery in Difficult-to-Treat Cancers The Results of this Pre-clinical Study Support a More Optimized Drug Delivery Method in Tumors that Lack Sufficient Blood Supply for Adequate Drug Penetration During Therapy RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath, an innovative, FDA-cleared device, highlighted its recent abstract presentation at the 2025 Society of Interventional Oncology Annual Conferen

Financing led by new fundamental healthcare institutional investors RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, an innovative, FDA-cleared delivery platform, today announced the closing of its previously announced $12.1 million firm commitment underwritten public offering of common stock led by multiple fundamental healthcare institutional investors. "We are very excited to close this common stock-only financing led by multiple high-quality fundamental healthcare institutional investors who are new to our company, which we view as a major achievement," said Shaun Bagai,

RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared delivery platform, today announced the pricing of a firm commitment, underwritten public offering of 11,523,810 shares of its common stock at a price to the public of $1.05 per share. All shares in the offering are being sold by RenovoRx. The gross proceeds from the offering are expected to be approximately $12.1 million before deducting underwriting discounts and commissions and offering expenses. The offering is expected to close on February 10, 2025, subject to satisfaction of customary closing conditions.

RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared delivery platform, today announced that it has commenced an underwritten public offering of shares of its common stock or pre-funded warrants to purchase shares of common stock. All of the securities to be sold in the proposed offering will be offered by RenovoRx. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. RenovoRx intends to use the net proceeds received from t